Phaseline

Companies › Biocells (Beijing) Biotech

Biocells (Beijing) Biotech: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Other; next expected readout Jul 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BXOS110–Phase 3AISJul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07520565BXOS110Phase 3AISOtherJul 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Huons Biopharma Neuren Pharmaceuticals Tetra Discovery Partners Prove pharm Neuraptive Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.